Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This report summarizes the current knowledge with respect to genetic changes associated with the development of prostate cancer. The relation between the occurrence of these changes and the stage of the disease is by far not clear yet, albeit that some tendencies become more or less evident. In Fig. 2 these are summarized. Whereas changes on 7q and loss or gain of the X chromosome are not consistently found by either RFLP or ISH analysis, other changes are (8p-, 10p-, 10q, 16q-, and 18q-). Clearly the picture is far from complete and even more the relevant genes on these chromosomes are not defined. E-cadherin was considered a good candidate and indeed the value as progression marker is great. However, the studies so far indicate that E-cadherin does not behave as a classical type I suppressor gene and the relation with 16q loss remains to be established. The data available to date regarding chromosomal changes in prostate cancer are limited. Many studies have to be pursued to identify the consistent changes, and moreover, to map the relevant loci harbouring the genes that are implicated in the development of this disease. This knowledge will be critical in the design of appropriate diagnostic methods and possibly clues towards therapy.
 ...
PMID:Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. 781 61

The recently detected TMPRSS2-ERG fusion gene was revealed as a recurrent and prevalent prostate cancer (PCa)-specific event, potentially qualifying it for clinical use. To detect this alteration, fluorescence in situ hybridization (FISH) is the method of choice. However, FISH has some disadvantages for widespread adoption in clinical practice. Subsequently, chromogenic in situ hybridization, which uses organic chromogens, and enzymatic metallography silver in situ hybridization have emerged as promising bright-field alternatives. Compared with chromogenic in situ hybridization, silver in situ hybridization signals are very distinct and superior with regard to signal clarity and resolution, but the method excludes multicolor protocols. Based on the ERG break-apart FISH assay, we established a dual-color ERG break-apart assay using combined chromogenic in situ hybridization and silver in situ hybridization (CS-ISH) and compared these results with those obtained by FISH. We assessed 178 PCa and 10 benign specimens for their ERG rearrangement status by applying dual-color FISH and CS-ISH ERG break-apart assays to consecutive sections. We observed a highly significant concordance (97.7%) between FISH- and CS-ISH-based results (Pearson's correlation coefficient = 0.955, P < 0.001). Our findings demonstrate that the ERG rearrangement status can reliably be assessed by CS-ISH. Further, the CS-ISH technique combines the accuracy and precision of FISH with the ease of bright-field microscopy. This tool allows a much broader spectrum of applications in which to study the biological role and clinical use of ERG rearrangements in PCa.
 ...
PMID:Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization. 2264 98